Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Health GroupHKSE:00673 24 3-Year ROIIC % is 31.76 as of Mar. 2026, which is 40% below its 10-year median of 52.54. GuruFocus rates HKSE:00673 with a GF Score™ of 24/100 and a GF Value™ of HK$0.24 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 116 Medical Distribution companies, China Health Group ranks better than 90.52% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
China Health Group's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 31.76%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for China Health Group's 3-Year ROIIC % or its related term are showing as below:
HKSE:00673's 3-Year ROIIC % is ranked better than 90.52% of 116
companies
in the Medical Distribution industry
Industry Median: 2.23
vs HKSE:00673: 31.76
China Health Group (HKSE:00673) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
China Health Group 3-Year ROIIC % Related Terms
China Health Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for China Health Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00673 vs MCK, COR, CAH: 3-Year ROIIC % Comparison
For the Medical Distribution subindustry, China Health Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Health Group 3-Year ROIIC % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China Health Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where China Health Group's 3-Year ROIIC % falls into.
China Health Group's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -33.5564963 (Mar. 2026) - -11.81 (Mar. 2023) )
/
( 56.168 (Mar. 2026) - 124.65 (Mar. 2023) )
=
-21.7464963
/
-68.482
=
31.76%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
China Health Group (HKSE:00673) has a 3-Year ROIIC % of 31.76 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on China Health Group and its competitors. This is 40% below median its historical median of 52.54. According to the industry distribution chart, China Health Group ranks #11 out of 116 companies in the Medical Distribution industry, placing it in the top 9.5%.
Is China Health Group's 3-Year ROIIC % too high?
China Health Group's current 3-Year ROIIC % of 31.76 is 40% below median its 10-year median of 52.54. The Medical Distribution industry median 3-Year ROIIC % is 2.23. China Health Group's value of 31.76 is 1324.2% above this industry median. Based on the distribution chart, China Health Group ranks #11 out of 116 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, China Health Group has a GF Score™ of 24/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Health Group's 3-Year ROIIC % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China Health Group ranks #11 out of 116 companies for 3-Year ROIIC %. This places China Health Group in the top 10% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 2.23. China Health Group's value of 31.76 is 1324.2% above this benchmark. While the company's 10-year median is 52.54 vs. the industry median of 2.23, China Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.23, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Health Group's current 3-Year ROIIC % of 31.76 is 1324.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on China Health Group and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Health Group's current 3-Year ROIIC % is 31.76, which is 40% below median its own 10-year median of 52.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Health Group stock overvalued right now?
Based on GuruFocus' analysis, China Health Group (HKSE:00673) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.24, compared to a current price of HK$0.31 — trading 29.2% above its estimated fair value. The current 3-Year ROIIC % is 31.76, which is 40% below median its 10-year median of 52.54 and 1324.2% above the Medical Distribution industry median of 2.23. China Health Group's overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For China Health Group (HKSE:00673), the current 3-Year ROIIC % is 31.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Health Group (HKSE:00673) Overvalued in 2026?
Based on GuruFocus' analysis, China Health Group stock appears to be overvalued.
The current stock price of HK$0.31 is trading 29.2% above its estimated GF Value™ of HK$0.24.
GuruFocus considers China Health Group to be Modestly Overvalued.
Key valuation signals for HKSE:00673:
3-Year ROIIC %: 31.76 (40% below median its 10-year median of 52.54)
GF Value™: HK$0.24 vs. price of HK$0.31 (29.2% above fair value)
Industry Position: 1324.2% above the Medical Distribution median (#11 of 116)
No single metric tells the full story. See the HKSE:00673 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Health Group Ltd is an investment holding company. It is principally engaged in the distribution and service of medical equipment and consumables, provision of hospital operation and management services, and business factoring. It operates in the business in four segments: medical equipment and consumables distribution and service business; hospital operation and management services business; business service; and research and development and sale of functional food. It derives a majority of revenue from the Distribution and service in the medical equipment and consumables segment. Geographically, the group derives its revenue from the PRC.
24GF Score
Get the complete analysis for HKSE:00673
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00673 has been successfully added to your 
